Platelet Esoteric Testing
A Case Study
GPS-Treatment
June 2010
The treatment options for gray platelet syndrome are platelet transfusion, DDAVP and recombinant factor VII administration. Myelofibrosis usually does not progress. However, sometimes patient may develop secondary pulmonary fibrosis similar to Hermansky-Pudlak syndrome.
GPS-Treatment |
Jump to section:
- Introduction
- Bleeding and Thrombosing Diseases: 2010 Mayo Update
- Clinical Presentation
- Bleeding History - 1
- Bleeding History - 2
- Complete Blood Count (CBC)
- Peripheral Blood Smear
- Coagulation Studies
- Platelet Function Studies
- Differential Diagnosis ?
- Laboratory Approach to Qualitative Platelet Disorders
- Platelet Qualitative Disorders
- Laboratory Systemic Approach
- Macro-thrombocytopenia
- Flow Cytometry Studies
- Platelet Activity By Flow Cytometry
- Macro-thrombocytopenia
- Ultrastructure Studies Whole Mount
- Ultrastructure Studies Thin Sections
- Macro-thrombocytopenia
- Molecular Studies
- Final Diagnosis
- Global Prevalence of GPS
- GPS-Clinical Presentation
- Laboratory Findings
- Differential Diagnoses of Gray Platelets
- Unique Bone Marrow Findings in Patients with GPS
- Clinical Presentation
- Myelofibrosis
- Emperipolesis
- GPS-Treatment
- Summary
- Acknowledgment
- Bleeding and Thrombosing Diseases: 2010 Mayo Update
- Questions?
External
link
PDF
document
Excel
document
Word
document